Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tango Therapeutics
Biotech
Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules
Tango has shuffled TNG908 off the dance floor, halting enrollment in a study of the cancer drug candidate to focus on two related molecules.
Nick Paul Taylor
Nov 6, 2024 8:28am
Tango drops USP1 inhibitor over liver toxicity in phase 1 trial
May 23, 2024 8:11am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Billy Dunn departs FDA—Chutes & Ladders
Mar 3, 2023 9:30am
Seagen finally finds new CEO—Chutes & Ladders
Nov 11, 2022 9:30am
Tango finds a quick step to Wall Street via $353M SPAC deal
Apr 14, 2021 10:39am
